Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 113

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 2
Chunk 113
---
iture-related items because the nature, size, timing and number of acquisitions and divestitures can vary dramatically from period-to-period and between the Company and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult.

Throughout this discussion, references to sales growth or decline refer to the impact of both price and unit sales and references to productivity improvements generally refer to improved cost-efficiencies resulting from the ongoing application of the Danaher Business System.

Sales Decline and Core Sales Growth

% Change Three-Month Period Ended March 28, 2025 vs. Comparable 2024 PeriodTotal sales decline (GAAP)(1.0)%Impact of:Acquisitions/divestitures(0.5)%Currency exchange rates 1.5 %Core sales growth (non-GAAP)— %

Operating Profit Performance 

Operating profit margins decreased 40 basis points from 22.6% during the three-month period ended March 29, 2024 to 22.2% for the three-month period ended March 28, 2025.  

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were unfavorably impacted by:

•The impact of product mix, reduced leverage on the Company’s operations and administrative cost structure and the impact of currency exchange rates - 30 basis points

•Incremental dilutive effect in 2025 of acquired businesses and the impact of a product line disposition which did not qualify as discontinued operations - 25 basis points

•First quarter 2025 impairment charge related to a facility in the Biotechnology segment - 25 basis points

23

First quarter 2025 vs. first quarter 2024 operating profit margin comparisons were favorably impacted by:

•First quarter 2024 acquisition-related fair value adjustment to inventory - 40 basis points

Business Segments

Sales by business segment for each of the periods indicated were as follows ($ in millions):

 Three-Month Period Ended March 28, 2025March 29, 2024Biotechnology$1,612 $1,524 Life Sciences1,680 1,745 Diagnostics2,449 2,527 Total$5,741 $5,796 

For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.

BIOTECHNOLOGY

The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables